Biogen (BIIB) Poised for rebound!
Biogen Inc CEO Michel Vounatsos Reports Open Market Purchase Of 3,100 Co's Common Shares After Hours Today!
Analyst Actions: RBC Capital Adjusts Biogen's Price Target to $256 From $249
aducanumab sales reps have not been laid off and are still instructed to educate doctors on disease state in preparation for FDA approval!
Oppenheimer sees Biogen (BIIB) as a "strategic fit" for collaboration with Sage Therapeutics (SAGE) in developing zuranolone and SAGE-324 due to its clinical expertise in neuroscience.
An FDA approval of aducanumab should garner a $100 per share jump!
The momentum of the company and new Sage relationship coupled with the actions of the CEO and salesforce strategy demonstrates confidence in the approval process and 2021 outlook of the company.
Positions 1/15/21 $230 call (1) 70 shares at $248
Who wants a non Chinese EV stock play???
Submitted December 02, 2020 at 04:06AM by feedyoursalesrep
via reddit https://ift.tt/33AlOKf